Published online Jul 6, 2024. doi: 10.12998/wjcc.v12.i19.3845
Revised: May 7, 2024
Accepted: May 13, 2024
Published online: July 6, 2024
Processing time: 111 Days and 23.3 Hours
Stromal cell derived factor-1 (SDF-1) plays a pivotal role in the recruitment of stem cells to injured livers. However, the changes of SDF-l in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) have yet to be elucidated.
To study the SDF-1 changes in patients with HBV-related ACLF.
30 patients with HBV-related ACLF, 27 patients with chronic hepatitis B and 20 healthy individuals are involved in our study. The SDF-l mRNA expression in liver tissue was detected by quantitative real-time polymerase chain reaction. Immunohistochemical staining was performed to illustrate the expression of SDF-l, CXC receptor 4 (CXCR4) and Ki67. The serum SDF-l concentrations were also detected by enzyme-linked immunosorbent assays.
The expression of SDF-1 mRNA from ACLF patients was remarkably higher than that from other patients (both P < 0.05). The expression of SDF-l, CXCR4 and Ki67 from ACLF were the highest among the three groups (all P < 0.01). The serum SDF-l levels in ACLF patients were significantly lower than that in other patients (both P < 0.01). Moreover, in ACLF patients, the serum SDF-1 Levels were positively correlated with serum total bilirubin and international normalized ratio. In addition, the serum SDF-l levels in survival were significantly lower compared with the non-survivals (P < 0.05). The area under the curve for the serum SDF-1 level in predicting 28-d mortality was 0.722 (P < 0.05).
This study provides the SDF-1 changes in patients with HBV-related ACLF. The SDF-1 Level at admission may serve as a promising prognostic marker for predicting short-term prognosis.
Core Tip: In this study, we investigated the changes in stromal cell derived factor-1 (SDF-1) in hepatitis B virus (HBV) associated acute-on-chronic liver failure (ACLF) patients. 30 HBV related ACLF patients, 27 chronic hepatitis B patients, and 20 healthy participants participated in our study. Our research findings provide information on the changes in SDF-1 in HBV associated ACLF patients. The level of SDF-1 at admission can serve as a promising prognostic marker for predicting short-term prognosis.